| Dec 25 | |
|---|---|
| Income Statement | |
| Total Revenue | $ 0.00 |
| Gross Profit | $ 0.00 |
| Operating Income | $ -91.29M |
| EBITDA | $ -91.25M |
| Net Income | $ -85.20M |
| Balance Sheet | |
| Cash & Short-Term Investments | $ 138.36M |
| Total Assets | $ 148.88M |
| Total Debt | $ 1.67M |
| Net Debt | $ -50.65M |
| Total Liabilities | $ 387.54M |
| Stockholders' Equity | $ -238.66M |
| Cash Flow | |
| Free Cash Flow | $ -81.83M |
| Operating Cash Flow | $ -81.48M |
| Investing Cash Flow | $ 10.06M |
| Financing Cash Flow | $ 99.79M |
Avalyn Pharma Inc (AVLN)
NASDAQ:AVLN
